<DOC>
	<DOCNO>NCT00117377</DOCNO>
	<brief_summary>The purpose study identify pimecrolimus cream 1 % modifies molecular cellular change associate post-lesional phase atopic dermatitis ( AD ) . Healthy volunteer patient atopic dermatitis study .</brief_summary>
	<brief_title>Effects Pimecrolimus Cream 1 % Molecular Cellular Profile Adult Male Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion patient atopic dermatitis : Outpatient screen Adult male &gt; 20 year old Diagnosis AD fulfil Hannifin Rajka criterion Mild moderate AD ( Investigator Global Assessment [ IGA ] 23 ; localize eczema area severity index [ EASI ] 18 ) AD affect arm and/or legs &gt; 10cm2 per target area Willing undergo 4 mm serial punch biopsy Patient history AD least 3 year Inclusion criterion healthy volunteer : Volunteers must males &gt; 20 year age Volunteers must good health , determine past medical history , physical examination , vital sign Exclusion criterion patient atopic dermatitis : Concurrent diseases/conditions history diseases/conditions Are immunocompromised history malignant disease Have history rheumatic fever , heart valve replacement , prosthetic joint prosthetic constituent Have concurrent skin disease ( e.g . acne ) severity study area could interfere study evaluation Have previously report poor clinical response topical tacrolimus ointment ( Protopic® ) pimecrolimus cream ( Elidel® ) Have active skin infection Present clinical condition atopic dermatitis interfere study treatment Present severe medical condition ( ) , opinion investigator , prohibit participation study Are maintain emollient contain supplementary ingredient urea , alpha betahydroxy acid , fruit acid , vitamins A , D E Have receive phototherapy ( e.g . UVA , UVB ) systemic therapy ( e.g . immunosuppressant , cytostatics ) know suspected effect AD within 4 week Visit 1 ( screen ) Have receive systemic corticosteroid ( [ CS ] e.g . oral , intravenous , intraarticular , rectal ) within 4 week Visit 1 ( screen ) . Patients stable maintenance dose inhale intranasal CS may participate Were treated topical therapy , include topical calcineurin inhibitor ( e.g . corticosteroid , tar ) know suspected effect AD current acute episode Were treat antihistamine within 7 day Visit 1 Known serious adverse reaction hypersensitivity anesthetic lidocaine mepivacaine Excluded investigational drugs/hypersensitivity Have receive investigational drug within 8 week first application study drug plan use investigational drug participation study Have know hypersensitivity ingredient pimecrolimus cream 1 % class study drug Exclusion criterion healthy volunteer : Erythrodermic patient , patient Netherton 's syndrome Personal family history atopy ( asthma , allergic rhinitis , atopic dermatitis ) Clinically significant finding physical examination Have history rheumatic fever , heart valve replacement , prosthetic joint prosthetic constituent e.g . lens implant hip joint Volunteers know serious adverse reaction hypersensitivity anesthetic lidocaine mepivacaine Participation clinical trial within one month prior current trial History immunocompromise History positive hepatitis B surface antigen ( HBsAg ) hepatitis C test result Use corticosteroid within 4 week prior baseline Were treat antihistamine within 7 day Visit 1 Phototherapy within 4 week prior baseline Topical therapy within 5 week prior study Treatment nephrotoxic drug within 2 week prior baseline ( aminoglycosides , amphotericin B , colchicine )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Atopic dermatitis , pimecrolimus , cellular , molecular</keyword>
</DOC>